×
About 20,499 results

ALLMedicine™ Pulmonary Fibrosis Center

Research & Reviews  10,045 results

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idi...
https://doi.org/10.1038/s41467-020-18397-6
Nature Communications; John AE, Graves RH et. al.

Sep 17th, 2020 - The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF). We identified a selective small molecule αvβ6 RGD-mimet...

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival...
https://doi.org/10.2217/bmm-2020-0165
Biomarkers in Medicine; Moll SA, Wiertz IA et. al.

Sep 17th, 2020 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year foll...

Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with ble...
https://doi.org/10.1080/03639045.2020.1825473
Drug Development and Industrial Pharmacy; Togami K, Maruta Y et. al.

Sep 17th, 2020 - Objective: Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic lung disease characterized by abnormal remodeling of the lung parenchyma with subsequent scarring of the alveolar structure. In this study, we examined the distribution ch...

Role of the Hippo signaling pathway in safflower yellow pigment treatment of paraquat-i...
https://doi.org/10.1177/0300060520905425
The Journal of International Medical Research; Li H, Kan B et. al.

Sep 17th, 2020 - To elucidate the molecular mechanisms by which safflower yellow (SY) mediates therapeutic effects in rats with paraquat intoxication-induced pulmonary fibrosis. Rats received combinations of paraquat, SY, and SB431542, a transforming growth factor...

Attenuation of Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats by Combination Treat...
https://doi.org/10.1080/01635581.2020.1820053
Nutrition and Cancer; Mehrzadi S, Hosseini P et. al.

Sep 16th, 2020 - The present study aimed to investigate the protective effects of two potent natural antioxidants, gallic acid and quercetin as single or combination treatment against bleomycin-induced pulmonary fibrosis (PF). A total of 50 Wistar rats were random...

see more →

Guidelines  25 results

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice G...
https://www.atsjournals.org/doi/10.1164/rccm.201807-1255ST
Raghu, G.

Aug 31st, 2018 - This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and.

Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society ...
https://cts-sct.ca/wp-content/uploads/2018/02/Evaluation-of-pts-w_ILD-paper.pdf
Kerri A. Johannson

Aug 21st, 2017 - Fibrotic ILD represents a large heterogeneous group of disorders that are challenging to diagnose. The evaluation of patients with fibrotic ILD should include a thorough history, physical examination, basic serological testing, pulmonary function.

Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fib...
http://www.thoracic.org/statements/resources/interstitial-lung-disease/animal-models-pulm-fibrosis.pdf
R. Gisli Jenkins

Apr 30th, 2017 - Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges associated with performing clini.

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.
https://doi.org/10.1159/000464332
Respiration; International Review of Thoracic Diseases; Funke-Chambour M, Azzola A et. al.

Mar 27th, 2017 - Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the c...

The Intersection of GERD, Aspiration, and Lung Transplantation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948126
Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A; Patti MG, Vela MF et. al.

May 24th, 2016 - Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking gastroesophagea...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  10,181 results

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idi...
https://doi.org/10.1038/s41467-020-18397-6
Nature Communications; John AE, Graves RH et. al.

Sep 17th, 2020 - The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF). We identified a selective small molecule αvβ6 RGD-mimet...

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival...
https://doi.org/10.2217/bmm-2020-0165
Biomarkers in Medicine; Moll SA, Wiertz IA et. al.

Sep 17th, 2020 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year foll...

Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with ble...
https://doi.org/10.1080/03639045.2020.1825473
Drug Development and Industrial Pharmacy; Togami K, Maruta Y et. al.

Sep 17th, 2020 - Objective: Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic lung disease characterized by abnormal remodeling of the lung parenchyma with subsequent scarring of the alveolar structure. In this study, we examined the distribution ch...

Role of the Hippo signaling pathway in safflower yellow pigment treatment of paraquat-i...
https://doi.org/10.1177/0300060520905425
The Journal of International Medical Research; Li H, Kan B et. al.

Sep 17th, 2020 - To elucidate the molecular mechanisms by which safflower yellow (SY) mediates therapeutic effects in rats with paraquat intoxication-induced pulmonary fibrosis. Rats received combinations of paraquat, SY, and SB431542, a transforming growth factor...

Attenuation of Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats by Combination Treat...
https://doi.org/10.1080/01635581.2020.1820053
Nutrition and Cancer; Mehrzadi S, Hosseini P et. al.

Sep 16th, 2020 - The present study aimed to investigate the protective effects of two potent natural antioxidants, gallic acid and quercetin as single or combination treatment against bleomycin-induced pulmonary fibrosis (PF). A total of 50 Wistar rats were random...

see more →

News  221 results

FDA broadens nintedanib interstitial lung disease indication
https://www.mdedge.com/internalmedicine/article/218826/pulmonology/fda-broadens-nintedanib-interstitial-lung-disease?channel=39313
Mitchel L. Zoler

Mar 11th, 2020 - A new indication for the tyrosine kinase inhibitor nintedanib approved by the Food and Drug Administration on March 9, 2020, broadened the drug’s targeted population to include patients with chronic fibrosing interstitial lung diseases with a prog.

Roche pushes to kick-start lung therapy Esbriet after big writedown
https://www.reuters.com/article/us-roche-esbriet/roche-pushes-to-kick-start-lung-therapy-esbriet-after-big-writedown-idUSKBN20Q21O

Mar 3rd, 2020 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable int...

Idiopathic pulmonary fibrosis in an era of personalized medicine
https://www.mdedge.com/pulmonary-health-hub/article/217385/pulmonology/idiopathic-pulmonary-fibrosis-era-personalized?channel=284
Lisa Hack

Feb 18th, 2020 - Useful not only as a clinical overview but also for patient information, these up-to-date statistics elucidate the symptoms and prevalence of pulmonary fibrosis; and recommendations for personalized treatment. To see the data in action, start read.

CHEST Foundation Casino Night promises fun for a good cause
https://www.mdedge.com/chestphysician/article/215886/society-news/chest-foundation-casino-night-promises-fun-good-cause?channel=28399

Feb 11th, 2020 - Keeping the momentum from our first-ever CHEST Foundation Reception and Casino Night at CHEST 2019, where champions in attendance raised more than $35,000 for pulmonary fibrosis research, the CHEST Foundation continues our long-standing partnershi.

Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
https://www.reuters.com/article/us-promedior-m-a-roche-hldg/roche-buys-u-s-drugmaker-promedior-for-up-to-1-4-billion-to-get-lung-drug-idUSKBN1XP1F0

Nov 15th, 2019 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Swiss drugmaker Roche is paying up to $1.4 billion to buy U.S. biotech company Pr...

see more →

Patient Education  23 results see all →